Chemical composition and anti-arthritic activity of Anacyclus valentinus extract on adjuvant-induced arthritis in rats

Anacyclus valentinus L. is a common annual plant in Algeria, known for her various therapeutic effects. In addition, the plant is used as a food condiment. We reported our investigations on the chemical compositions and the antiarthritic activity of methanolic extract of A. valentinus (MEAV). The polyphenol extraction by maceration with methanol (80%) gave yields of 17.82%. The identification by LC-MS and colorimetric assays revealed the wealth of methanolic extracts on phenolic compounds including flavonoids (52.15 mg Equ/g) and lactones. Acute oral toxicity of extract was performed in line with OECD guidelines and the lethal dose 50 was assessed greater than 2500 mg/Kg. Regarding the anti-arthritic power, rheumatoid arthritis was induced by Freund\u27s adjuvant in rats. The methanolic extract of A. valentinus presented a largest effect with weight gain, an arthritic score, thymus indices; spleen and serum parameters close to those of the control. The extract also inhibited edema and restored cartilage structure

growth of zno nanorods on fto glass substrate

n/

Elaboration and Characterization of ZnO/FTO thin films under different concentrations - Study dedicated to the photovoltaic systems - Study d

© 2020 IEEE. This paper presents an elaboration of thin films dedicated to photovoltaic systems. Zinc oxide (ZnO) on fluorine tin oxide (FTO) coated glass substrates are one of the best semiconductors oriented to solar cell preparations. In this study, the ZnO solution is performed with some sol concentration (0.1 M to 0.5 M) to verify its effect on thin-film samples. On the other hand, samples prepared are analyzed and characterized in structural and the optical properties using different techniques as ultraviolet-visible (UV-vis) spectrometry, Fourier transform infrared spectroscopy (FT-IR) and X-ray diffraction (XRD). This work showed the variation of the energy gap (Eg) values. The Eg values allow us to ensure good solar cells. In this study, the thin films prepared showed that the energy gap values are ranged between 3.29 eV and 3.4 eV. These results led us to confirm the possibility of having an easy passage of the electrical current. In addition, the transmittance spectra of the ZnO/FTO thin films showed an average of ~75% in the visible region and presented sharp absorption edges at 375 nm. The experimental preparation ensures a good decision about electrical energy production which based on the photovoltaic systems

Additional evidence for the role of chromosomal imbalances and SOX8, ZNRF3 and HHAT gene variants in early human testis development

Abstract Background Forty-six ,XY Differences/Disorders of Sex Development (DSD) are characterized by a broad phenotypic spectrum ranging from typical female to male with undervirilized external genitalia, or more rarely testicular regression with a typical male phenotype. Despite progress in the genetic diagnosis of DSD, most 46,XY DSD cases remain idiopathic. Methods To determine the genetic causes of 46,XY DSD, we studied 165 patients of Tunisian ancestry, who presented a wide range of DSD phenotypes. Karyotyping, candidate gene sequencing, and whole-exome sequencing (WES) were performed. Results Cytogenetic abnormalities, including a high frequency of sex chromosomal anomalies (85.4%), explained the phenotype in 30.9% (51/165) of the cohort. Sanger sequencing of candidate genes identified a novel pathogenic variant in the SRY gene in a patient with 46,XY gonadal dysgenesis. An exome screen of a sub-group of 44 patients with 46,XY DSD revealed pathogenic or likely pathogenic variants in 38.6% (17/44) of patients. Conclusion Rare or novel pathogenic variants were identified in the AR, SRD5A2, ZNRF3, SOX8, SOX9 and HHAT genes. Overall our data indicate a genetic diagnosis rate of 41.2% (68/165) in the group of 46,XY DSD

A regionally based precision medicine implementation initiative in North Africa:The PerMediNA consortium

International audiencePrecision Medicine is being increasingly used in the developed world to improve health care. While several Precision Medicine (PM) initiatives have been launched worldwide, their implementations have proven to be more challenging particularly in low- and middle-income countries. To address this issue, the “Personalized Medicine in North Africa” initiative (PerMediNA) was launched in three North African countries namely Tunisia, Algeria and Morocco. PerMediNA is coordinated by Institut Pasteur de Tunis together with the French Ministry for Europe and Foreign Affairs, with the support of Institut Pasteur in France. The project is carried out along with Institut Pasteur d’Algérie and Institut Pasteur du Maroc in collaboration with national and international leading institutions in the field of PM including Institut Gustave Roussy in Paris. PerMediNA aims to assess the readiness level of PM implementation in North Africa, to strengthen PM infrastructure, to provide workforce training, to generate genomic data on North African populations, to implement cost effective, affordable and sustainable genetic testing for cancer patients and to inform policy makers on how to translate research knowledge into health products and services. Gender equity and involvement of young scientists in this implementation process are other key goals of the PerMediNA project.In this paper, we are describing PerMediNA as the first PM implementation initiative in North Africa. Such initiatives contribute significantly in shortening existing health disparities and inequities between developed and developing countries and accelerate access to innovative treatments for global health